Please login to the form below
rheumatoid arthritis
This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.
Alnylam swaps Sanofi for Regeneron as R&D partner
that resulted in commercial products including cholesterol therapy Praluent (alirocumab), Dupixent (dupilumab) for atopic dermatitis and rheumatoid arthritis therapy Kevzara (sarilumab).
Latest news
-
Gilead and Galapagos close in on filing for Xeljanz rival
Belgian biotech gearing up for first approval. Galapagos and Gilead Sciences have a pair of positive phase 3 trials for their JAK inhibitor filgotinib in rheumatoid arthritis that they say make ... RA and the rest from other diseases such as psoriatic
-
AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod
Risankizumab is also being in clinical trials for a number of other inflammatory diseases, including Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. ... AbbVie has another inflammation treatment nearing the market,
-
EMA could follow FDA’s Xeljanz blood clot warning
Xeljanz is currently approved in both the US and EU for patients with rheumatoid arthritis (RA) and psoriatic arthritis, but at an authorised dose of 5mg, twice daily. ... In the EU and the US, this dose is higher than the authorised dose of 5 mg twice
-
Sanofi extends growth spurt thanks to Genzyme, Dupixent
Other new products in Sanofi’s portfolio are still not looking too buoyant, particularly Kevzara (sarilumab) for rheumatoid arthritis and high cholesterol therapy Praluent (alirocumab), both of which have struggled to
-
Gilead awaits CEO and readouts to revive fortunes
and the fatty liver disease non-alcoholic steatohepatitis (NASH) and selective JAK1 inhibitor f ilgotinib in rheumatoid arthritis. ... Also of great importance are two phase 3 studies, FINCH 1 and FINCH 3 of filgotinib in rheumatoid arthritis.
More from news
Approximately 55 fully matching, plus 398 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that
-
Finding the patient voice
rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.
-
The tipping point
In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.
-
Mobile health and patient outcomes
In a recent study in rheumatoid arthritis, patients saw pain as the key measure of treatment success, confounding the objective ‘clinical evidence’ of improvement.
-
Grünenthal's relentless pursuit of relief
Pain has nervous and inflammatory components and we are interested in everything around the inflammatory process but also the central nervous system aspect of pain and adjunctive diseases such as rheumatoid ... arthritis and Parkinson’s.
More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest appointments
-
Portland Health appoints Jamie Hewitt as an account director
He joins the firm from the National Rheumatoid Arthritis Society, where he was its head of government affairs, leading the policy and public affairs functions. ... During his time at the National Rheumatoid Arthritis Society, Hewitt ran UK campaigns to
-
Liberation Unlimited promotes Vicky Smith
oncology, rheumatoid arthritis and eye health.
-
Galapagos appoints Bart Filius as chief financial officer
His vast experience in big pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
-
Liberation promotes Danielle Smith to account director
Meanwhile, Vicky joined Liberation last year and in her new role will continue to work across a range of therapeutic areas including men's health, rheumatoid arthritis and eye health.
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data. Click here
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several
-
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada.
-
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU &Japan) 2019 report. ... The qualitative interviews will be enhanced with insights generated from pre-interview patient exercises – such as patient diary entries - to
-
NHS medicines optimisation milestone
for a population of patients with Rheumatoid Arthritis. To achieve this, pharma needs to consider issues such as treatment failure rates; inpatient stays, the impact on social care and a
More from PMHub
Approximately 8 fully matching, plus 18 partially matching documents found.
Featured jobs
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Senior Medical Writer
-
Competitive salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
